Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release terzapide supplier its latest quarterly report later this week. Analysts are anticipating strong performance driven by the robust sales of Lilly's blockbuster treatments, particularly the diabetes franchise. However, there are also concerns abou